Ginkgo Bioworks (DNA) CEO Jason R Kelly Sells $463K of Stock

Chief Executive Officer & Founder Jason R Kelly sold 45,682 shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) on October 19, 2026. According to a Form 4 filed with the SEC, the shares were sold at a price of $10.14 each, totaling about $463,352.53. The transaction reduced the executive's direct holdings down to 129,065 shares, marking a 26.14% drop in his stake. The stock closed at $10.07 on the day of the trade.

DNA Ginkgo Bioworks Holdings, Inc.

$10.01 ▲ +15.06% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Inside Jason R Kelly's Ginkgo Bioworks Trade

The transaction left the chief executive with 129,065 shares of the company following the sale. This Form 4 filing was not executed under a pre-arranged Rule 10b5-1 trading plan. The trade price of $10.14 per share sat slightly above the stock's closing price of $10.07 on October 19, 2026.

Other Institutional Activity in Ginkgo Bioworks

Large financial firms have adjusted their positions in the biotechnology company over recent reporting periods. Viking Global Investors, L.P. maintained its stake, holding 3,577,128 shares valued at about $35,807,052. Erste Asset Management GmbH grew its holdings by 589,193 shares, ending with 2,536,939 shares worth about $25,394,759, which is a 30.2% increase. BAILLIE GIFFORD & CO kept its position steady at 2,391,649 shares worth about $23,940,407. Anchorage Capital Group, LLC held 1,746,363 shares valued at about $1,748,1094 with no change in share count. Legal & General Group PLC added 7,810 shares, growing its stake by 0.5% to 1,669,419 shares worth about $1,671,088.40.

Ginkgo Bioworks Holdings, Inc. Stock Down 1.3%

Shares of Ginkgo Bioworks recently traded around $9.73 as of October 21, 2026, which is down about 3.4% from the event-day close of $10.07. The stock has traded between a 52-week low of $5.37 and a 52-week high of $18.22. Recent prices put the shares above both their 50-day moving average of $8.92 and their 200-day moving average of $8.52.

Recent Earnings

Ginkgo Bioworks Holdings, Inc. reported trailing-twelve-month revenue of $132,421,000 alongside an earnings per share of -$5.06. The company posted a net profit margin of -219.6% and a return on equity of -59.9%. Its quick ratio sits at 4.33, while the current ratio is 4.57, and the debt-to-equity ratio rests at 96.15. The firm's next quarterly financial results are scheduled for release on November 5, 2026. The company previously saw insider transactions earlier in the year, including a purchase by director Christian Henry noted in prior coverage on June 11, 2026.

Insider Buying and Selling at Ginkgo Bioworks Holdings, Inc.

Insider transactions over the prior months included several moves by company executives and board members. Chief Financial Officer Steven P. Coen sold 752 shares on July 17, 2026, at an average price of $7.90 for a total value of $5,943. Coen later sold 330 shares on August 24, 2026, at $6.98 per share, totaling $2,302. Director Christian O Henry sold 5,000 shares on September 15, 2026, at $7.08 per share for a value of $35,405. Additionally, Coen sold 2,403 shares on October 5, 2026, at $15.00 per share, worth $36,045.

Analysts Set New Price Targets

Wall Street firms have updated their outlooks on the stock across recent months. TD Cowen downgraded the stock to a hold rating on August 7, 2026, lowering its price target from $12.00 to $9.00. BTIG reiterated a sell rating on September 4, 2026, keeping its price target at $5.00. TD Cowen later maintained a hold rating on October 13, 2026, lifting its price target from $9.00 to $11.00. The stock carries a consensus recommendation of underperform from two analyst opinions, with a mean price target of $8.00.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc. builds a platform designed for cell engineering in the United States. Operating through both cell engineering and biosecurity segments, the Boston-based company supports clients across various industries looking to program cells. This insider sale by the chief executive comes as the firm prepares for its upcoming earnings release.

Bottom Line

Investors will look toward the upcoming earnings report on November 5, 2026, for further updates on Ginkgo Bioworks' financial performance. Form 4 filings provide official records of executive trades as they occur. Stakeholders continue to monitor management transactions alongside broader institutional positioning.